Immunotoxins and Other Conjugates Containing Saporin-S6 for Cancer Therapy

被引:58
作者
Polito, Letizia [1 ]
Bortolotti, Massimo [1 ]
Pedrazzi, Manuela [1 ]
Bolognesi, Andrea [1 ]
机构
[1] Alma Mater Studiorum Univ Bologna, Dept Expt Pathol, I-40126 Bologna, Italy
来源
TOXINS | 2011年 / 3卷 / 06期
关键词
saporin-S6; plant toxins; immunotoxins; immunoconjugates; immunotherapy; anti-cancer therapy; RIBOSOME-INACTIVATING PROTEINS; ACUTE LYMPHOBLASTIC-LEUKEMIA; B-CELL LYMPHOMA; GROWTH-FACTOR-SAPORIN; COMBINED IMMUNODEFICIENT MICE; MONOCLONAL-ANTIBODY; IN-VITRO; BISPECIFIC ANTIBODIES; ANTITUMOR-ACTIVITY; HODGKINS-DISEASE;
D O I
10.3390/toxins3060697
中图分类号
TS2 [食品工业];
学科分类号
0832 ;
摘要
Ribosome-inactivating proteins (RIPs) are a family of plant toxins that permanently damage ribosomes and possibly other cellular substrates, thus causing cell death. RIPs are mostly divided in two types: Type 1 RIPs that are single-chain enzymatic proteins, and type 2 RIPs that consist of an active A chain (similar to a type 1 RIP) linked to a B chain with lectin properties. RIP-containing conjugates have been used in many experimental strategies against cancer cells, often showing great efficacy in clinical trials. Saporin-S6, a type 1 RIP extracted from Saponaria officinalis L. seeds, has been extensively utilized to construct anti-cancer conjugates because of its high enzymatic activity, stability and resistance to conjugation procedures, resulting in the efficient killing of target cells. This review summarizes saporin-S6-containing conjugates and their application in cancer therapy, considering in-vitro and in-vivo studies both in animal models and in clinical trials. The review is structured on the basis of the targeting of hematological versus solid tumors and on the antigen recognized on the cell surface.
引用
收藏
页码:697 / 720
页数:24
相关论文
共 85 条
  • [1] Inhibition of Tumor Growth by Targeted Toxins in Mice is Dramatically Improved by Saponinum Album in a Synergistic Way
    Bachran, Christopher
    Duerkop, Horst
    Sutherland, Mark
    Bachran, Diana
    Mueller, Christian
    Weng, Alexander
    Melzig, Matthias F.
    Fuchs, Hendrik
    [J]. JOURNAL OF IMMUNOTHERAPY, 2009, 32 (07) : 713 - 725
  • [2] Battelli MG, 1996, INT J CANCER, V65, P485, DOI 10.1002/(SICI)1097-0215(19960208)65:4<485::AID-IJC16>3.0.CO
  • [3] 2-9
  • [4] IN-VIVO AND IN-VITRO UPTAKE OF AN ANTI-CD30/SAPORIN IMMUNOTOXIN BY RAT-LIVER PARENCHYMAL AND NONPARENCHYMAL CELLS
    BATTELLI, MG
    BUONAMICI, L
    BOLOGNESI, A
    STIRPE, F
    [J]. HEPATOLOGY, 1994, 20 (04) : 940 - 947
  • [5] BEITZ JG, 1992, CANCER RES, V52, P227
  • [6] KILLING OF K562 CELLS WITH CONJUGATES BETWEEN HUMAN TRANSFERRIN AND A RIBOSOME-INACTIVATING PROTEIN (SO-6)
    BERGAMASCHI, G
    CAZZOLA, M
    DEZZA, L
    SAVINO, E
    CONSONNI, L
    LAPPI, D
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 1988, 68 (03) : 379 - 384
  • [7] Evaluation of immunotoxins containing single-chain ribosome-inactivating proteins and an anti-CD22 monoclonal antibody (OM124):: in vitro and in vivo studies
    Bolognesi, A
    Tazzari, PL
    Olivieri, F
    Polito, L
    Lemoli, R
    Terenzi, A
    Pasqualucci, L
    Falini, B
    Stirpe, F
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 1998, 101 (01) : 179 - 188
  • [8] In vitro anti-tumour activity of anti-CD80 and anti-CD86 immunotoxins containing type 1 ribosome-inactivating proteins
    Bolognesi, A
    Polito, L
    Tazzari, PL
    Lemoli, RM
    Lubelli, C
    Fogli, M
    Boon, L
    De Boer, M
    Stirpe, F
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2000, 110 (02) : 351 - 361
  • [9] Bolognesi A, 2005, J BIOL REG HOMEOS AG, V19, P145
  • [10] BOLOGNESI A, 1992, CLIN EXP IMMUNOL, V89, P341